A new report published on Tuesday 25 February, produced by R-Health Consult and commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA), analyses the economic and health benefits of investing in five noncommunicable diseases in the EU.
The report focuses on stroke, ischaemic heart disease, type 2 diabetes, chronic obstructive pulmonary disease (COPD) and breast cancer in the 27 EU Member States, and makes recommendations on how to reduce mortality, improve patients’ quality of life and increase return on investment for the European economy.
It shows that achieving substantial return on investment is possible through targeted health interventions, and is based on case studies from three countries: Portugal, Romania and Sweden.
Details: https://aeur.eu/f/fne (Original version in French by Lionel Changeur)